INBRX-109 in Ewing Sarcoma and Gastrointestinal Stromal Tumor (GIST)

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking a study drug called INBRX-109. The overall goal of the study is to find out how safe and effective the study drug is in treating people that have been diagnosed with advanced or metastatic Ewing sarcoma or SDH-deficient solid tumor/Gastrointestinal Stromal Tumor (GIST).

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT03715933

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
23-021736
Official Title:
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas
Study Phase:
Phase I
Eligible Age Range:
12 - 29 Years
Gender:
All
Study Categories:

Visit Criteria

The study will enroll patients between 12 and 29 years of age that have been diagnosed with an advanced or metastatic Ewing sarcoma or SDH-deficient solid tumor/Gastrointestinal Stromal Tumor (GIST). As a participant in this research, you will:

  • Receive a study drug called INBRX-109
  • Have research blood tests
  • Submit tissue samples from past tumor biopsies
  • Have extra or leftover tissue collected if you have a biopsy as a part of your regular cancer care
Leader
Theodore W. Laetsch

Theodore Laetsch, MD